cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1212Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESБезопасность статинов: реальное и надуманноеStatin safety: myths and realityКобалаваЖ. Д.KobalavaZh. D.zkobaleva@mail.ruВиллевальдеС. В.VillevaldeS. V.zkobaleva@mail.ruШавароваЕ. К.ShavarovaE. K.zkobaleva@mail.ruРоссийский университет дружбы народов, МоскваRussian University of People's Friendship, Moscow20072004200762105112Copyright © Кобалава Ж.Д., Виллевальде С.В., Шаварова Е.К., 20072007Кобалава Ж.Д., Виллевальде С.В., Шаварова Е.К.Kobalava Z.D., Villevalde S.V., Shavarova E.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1212

Расширение показаний к назначению препаратов группы статинов для достижения более низких целевых значений липопротеинов низкой плотности и повышение используемых доз статинов сопряжено с неизбежным увеличением числа возникающих побочных реакций. В данной статье представлен анализ соотношения положительного влияния статинов с риском развития нежелательных эффектов в отношении печени, мышечной и нервной тканей, почек.

More frequent statin prescription, to achieve lower target low-density lipoprotein levels, as well as statin dose increase, is associated with inevitable raise in adverse event rates. The article compares statin benefits and the risk of adverse liver, muscle, brain, and kidney effects.

дислипопротеинемиястатиныпобочные эффектыdyslipoproteinemiastatinsadverse effectsReferencesBaigent C. Cholesterol Treatment Trialists’ (CTT) collaborators. Lancet 2005; 366: 1267-78.Baigent C. Cholesterol Treatment Trialists’ (CTT) collaborators. Lancet 2005; 366: 1267-78.National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III. JAMA 2001; 285: 2486-97.National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III. JAMA 2001; 285: 2486-97.Grundy SM, Cleemam JI, Merz CNB, et al. National Heart, Lung, and Blood Institute, American College of Cardiology Foundation and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227-39.Grundy SM, Cleemam JI, Merz CNB, et al. National Heart, Lung, and Blood Institute, American College of Cardiology Foundation and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227-39.Bays H. Statin safety: an overview and assessment of the data -2005. Am J Cardiol 2006; 97 (8A): 6C-27.Bays H. Statin safety: an overview and assessment of the data -2005. Am J Cardiol 2006; 97 (8A): 6C-27.Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97 (8A): 69С-77.Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97 (8A): 69С-77.Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97 (8A): 77С-82.Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97 (8A): 77С-82.Kasiske BL, Warnner C, O’Nill WC. An assessment of statin safety by nephrologists. Am J Cardiol 2006; 97 (8A): 82С-6.Kasiske BL, Warnner C, O’Nill WC. An assessment of statin safety by nephrologists. Am J Cardiol 2006; 97 (8A): 82С-6.Brass LM, Alberts MJ, Sparks L. An assessment of statin safety by neurologists. Am J Cardiol 2006 97 (8A): 86С-9.Brass LM, Alberts MJ, Sparks L. An assessment of statin safety by neurologists. Am J Cardiol 2006 97 (8A): 86С-9.McKenney JM, Davidson MH, Jacobson TA. Final conclusions and recommendations of the NLA Statin Safety Task Force. Am J Cardiol 2006; 97 (8A): 89С-96.McKenney JM, Davidson MH, Jacobson TA. Final conclusions and recommendations of the NLA Statin Safety Task Force. Am J Cardiol 2006; 97 (8A): 89С-96.Guyton JR. Benefit versus risk in statin treatment. Am J Cardiol 2006; 97 (8A): 96С-9.Guyton JR. Benefit versus risk in statin treatment. Am J Cardiol 2006; 97 (8A): 96С-9.Lipitor (atorvastatin). New York, NY: Pfizer Inc. 2004.Lipitor (atorvastatin). New York, NY: Pfizer Inc. 2004.Vytorin (ezetimibe4simvastatin). North Wales, PA: Merck/Schering4Plough Pharmaceuticals 2005.Vytorin (ezetimibe4simvastatin). North Wales, PA: Merck/Schering4Plough Pharmaceuticals 2005.Zetia (ezetimibe). North Wales, PA: Merck/Schering4Plough Pharmaceuticals 2005.Zetia (ezetimibe). North Wales, PA: Merck/Schering4Plough Pharmaceuticals 2005.Pasternak RC, Smith SC Jr, Bairey4Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. JACC 2002; 40: 567-72.Pasternak RC, Smith SC Jr, Bairey4Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. JACC 2002; 40: 567-72.Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs, din Uver Dis 2003; 7: 415-33.Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs, din Uver Dis 2003; 7: 415-33.Gotto AM Jr. The case for over-the-counter statins. Am J Cardiol 2004; 94: 753-6.Gotto AM Jr. The case for over-the-counter statins. Am J Cardiol 2004; 94: 753-6.Mevacor (lovastarin). Whitehouse Station, NJ: Merck& Co. Inc. 2005.Mevacor (lovastarin). Whitehouse Station, NJ: Merck& Co. Inc. 2005.Zocor (simvastatin), Whitehouse Station, NJ: Merck& Co. Inc. 2004.Zocor (simvastatin), Whitehouse Station, NJ: Merck& Co. Inc. 2004.Lescol (fluvastatin). East Hanover, NJ: Novartis; 2003,Lescol (fluvastatin). East Hanover, NJ: Novartis; 2003,Pravachol (pravastatin). Princeton, NJ; Bristol-MyersSquibb 2004,Pravachol (pravastatin). Princeton, NJ; Bristol-MyersSquibb 2004,Crestor (rosuvastatin). Wilmington, DE; AstraZeneca 2005.Crestor (rosuvastatin). Wilmington, DE; AstraZeneca 2005.de Denus S, Spinier SA, Miller K, et al. Statins and liver toxicity: a meta analysis. Pharmactiherapy 2004; 24: 584-91.de Denus S, Spinier SA, Miller K, et al. Statins and liver toxicity: a meta analysis. Pharmactiherapy 2004; 24: 584-91.Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring for statin use? Am J Cardiol 2004; 94(Suppl): 30F-4.Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring for statin use? Am J Cardiol 2004; 94(Suppl): 30F-4.Vuppalanchi R, Teal E, Chalasani N. Patients with elevated base-line liver enzymes do not have higher frequency of hepatoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62-5.Vuppalanchi R, Teal E, Chalasani N. Patients with elevated base-line liver enzymes do not have higher frequency of hepatoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62-5.Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-92.Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-92.Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 4(1): 690-5.Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 4(1): 690-5.Bays H, Abate N, Chandalia M. Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiology 2005; 1: 39-59.Bays H, Abate N, Chandalia M. Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiology 2005; 1: 39-59.Bays H, Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther 2005; 3: 393-404.Bays H, Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther 2005; 3: 393-404.Chitturi S, George J. Hepatotoxicity of commonly used drugs: non4steroidal anti4inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-83.Chitturi S, George J. Hepatotoxicity of commonly used drugs: non4steroidal anti4inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-83.Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-92.Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-92.Bottorff MB. Safety and statins: pharmacologic and clinical perspectives, Am J Manag Care 2004; 4(Suppl 2): S27-37.Bottorff MB. Safety and statins: pharmacologic and clinical perspectives, Am J Manag Care 2004; 4(Suppl 2): S27-37.Hunninghake DB. Drug treatment of dyslipoproteinemia. Endocrinol Metab Clin North Am 1990; 19: 345-60.Hunninghake DB. Drug treatment of dyslipoproteinemia. Endocrinol Metab Clin North Am 1990; 19: 345-60.Piorkowski JD Jr. Bayer’s response to «potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.» JAMA 2004; 292: 2655-7.Piorkowski JD Jr. Bayer’s response to «potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.» JAMA 2004; 292: 2655-7.Gotto AM. Safety and statin therapy. Reconsidering the risks and benefits. Arch Intern Med 2003; 163: 657-9.Gotto AM. Safety and statin therapy. Reconsidering the risks and benefits. Arch Intern Med 2003; 163: 657-9.Pelli N, Setti M, Ceppa P, et al. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 2003; 15: 921-4.Pelli N, Setti M, Ceppa P, et al. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 2003; 15: 921-4.Siddiqui J, Raina D, Abraham A, et al. Autoimmune hepatitis induced by statins [abstract]. Gastroenterology 2005; 128: A171.Siddiqui J, Raina D, Abraham A, et al. Autoimmune hepatitis induced by statins [abstract]. Gastroenterology 2005; 128: A171.Neuschwanter-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.Neuschwanter-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.Law M, Rudnicka AR. Statin safety: a systemic review. Am J Cardiol 2006; 97(Suppl): 52C-60.Law M, Rudnicka AR. Statin safety: a systemic review. Am J Cardiol 2006; 97(Suppl): 52C-60.Pasternak RC, Smith SC Jr, Bairey4Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. JACC 2002; 40: 567-72.Pasternak RC, Smith SC Jr, Bairey4Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. JACC 2002; 40: 567-72.Staffa JA, Chang I, Green L. Cerivastatin and reports of fatal rhab4 domyolysis. N Engl J Med 2002; 346: 539-40.Staffa JA, Chang I, Green L. Cerivastatin and reports of fatal rhab4 domyolysis. N Engl J Med 2002; 346: 539-40.Evans M, Rees A. Effects of HMG4CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25: 649-63.Evans M, Rees A. Effects of HMG4CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25: 649-63.Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-107.Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-107.Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116: 408-16.Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116: 408-16.Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140-6.Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140-6.Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97(Suppl): 27C-31.Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97(Suppl): 27C-31.Bays H, Dujovne C. Colesevelam HC1: a non-systemic lipidaltering drug. Expert Opin Pharmacother 2003; 4: 779-90.Bays H, Dujovne C. Colesevelam HC1: a non-systemic lipidaltering drug. Expert Opin Pharmacother 2003; 4: 779-90.Bays H, Stein EA. Pharmacotherapy for dyslipidaemia – current therapies and future agents. Expert Opin Pharmacother 2003; 4: 1901-38.Bays H, Stein EA. Pharmacotherapy for dyslipidaemia – current therapies and future agents. Expert Opin Pharmacother 2003; 4: 1901-38.Covington MB. Omega-3 fatty acids. Am Fam Physician 2004; 70: 133-40.Covington MB. Omega-3 fatty acids. Am Fam Physician 2004; 70: 133-40.Agarwal R. Statin induced proteinuria: renal injury or renopro4 tection? Am J Soc Nephrol 2004; 15: 2502-3.Agarwal R. Statin induced proteinuria: renal injury or renopro4 tection? Am J Soc Nephrol 2004; 15: 2502-3.Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the Adverse Event Reporting System. Am J Cardiol 2006; 97(Suppl): 32C-43.Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the Adverse Event Reporting System. Am J Cardiol 2006; 97(Suppl): 32C-43.Tonelli M, Moye L, Sacks F, et al. for the Cholesterol and Recurrent Events (CARE) Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605-13.Tonelli M, Moye L, Sacks F, et al. for the Cholesterol and Recurrent Events (CARE) Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605-13.Kasiske BL, Wanner C, O’Neill WC. An assessment of statin safety by nephrologists. Am J Cardiol 2006; 97(Suppl): 82C-5.Kasiske BL, Wanner C, O’Neill WC. An assessment of statin safety by nephrologists. Am J Cardiol 2006; 97(Suppl): 82C-5.Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials. Circulation 2002; 105: 2341-6.Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials. Circulation 2002; 105: 2341-6.Christensen El. Pathophysiology of protein and vitamin handling in the proximal tubule. Nephrol Dial Transplan 2002; 17(Suppl 9): 57-8.Christensen El. Pathophysiology of protein and vitamin handling in the proximal tubule. Nephrol Dial Transplan 2002; 17(Suppl 9): 57-8.Sidaway IE, Davidson RG. McTaggart F, et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J 125Am Soc Nephrol 2004; 15: 2258-65.Sidaway IE, Davidson RG. McTaggart F, et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J 125Am Soc Nephrol 2004; 15: 2258-65.US Department of Health and Human Services. US Food and Drug Administration Center for Drug Evaluation and Research, Transcript of meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. July 9, 2003. [FDA Web site.] Available at: http:// www.fda.gov/ohrms/dockets/ac/03/tran4 scripts/3968Tl.doc. Accessed February 6, 2006.US Department of Health and Human Services. US Food and Drug Administration Center for Drug Evaluation and Research, Transcript of meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. July 9, 2003. [FDA Web site.] Available at: http:// www.fda.gov/ohrms/dockets/ac/03/tran4 scripts/3968Tl.doc. Accessed February 6, 2006.Verhulst A, D’Haese PC, De Broe ME. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004; 15: 2249-57.Verhulst A, D’Haese PC, De Broe ME. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004; 15: 2249-57.Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-70.Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-70.Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-9.Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-9.Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.Bays HE. Collaborative Atorvastatin Diabetes Study (CARDS). Lipids Online Commentaries on Research 2005. Available at: http://www.lipidsonline.org. Accessed February 6, 2006.Bays HE. Collaborative Atorvastatin Diabetes Study (CARDS). Lipids Online Commentaries on Research 2005. Available at: http://www.lipidsonline.org. Accessed February 6, 2006.King DS, Wilburn AJ, Wofford MR, et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003; 23: 1663-7.King DS, Wilburn AJ, Wofford MR, et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003; 23: 1663-7.Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001; 21: 767-9.Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001; 21: 767-9.Muldobn MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000; 108: 538-46.Muldobn MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000; 108: 538-46.Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004; 117: 823-9.Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004; 117: 823-9.Yaffe K, Barrett4Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function, in older women. Arch Neurol 2002; 59: 378-84.Yaffe K, Barrett4Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function, in older women. Arch Neurol 2002; 59: 378-84.Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004; 63: 1624-8.Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004; 63: 1624-8.Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial. Lancet 2002; 60: 1623-30.Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial. Lancet 2002; 60: 1623-30.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.Golomb BA. Implications of statin adverse effects in the elderly. Expert Opin Drug Saf 2005; 4: 389-97.Golomb BA. Implications of statin adverse effects in the elderly. Expert Opin Drug Saf 2005; 4: 389-97.Amarenco P, Tonkin AM. Statins for stroke prevention; disappointment and hope. Circulation 2004; 109(Suppl l): III44-9.Amarenco P, Tonkin AM. Statins for stroke prevention; disappointment and hope. Circulation 2004; 109(Suppl l): III44-9.Amarenco P, Lavallee P, Touboul PJ. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004; 3: 271-8.Amarenco P, Lavallee P, Touboul PJ. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004; 3: 271-8.Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423-30.Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423-30.Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-67.Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-67.Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62: 753-7.Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62: 753-7.Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58: 1333-7.Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58: 1333-7.Boh M, Opolski G, Polonski L, et al. Polownanie skutecznosci i bezpieczenstwa stosowania atorwastatyny generycznej i referencyjnej u osob zwiekszonego ryzyka wiencowego z hiperlipidemia. Wydanie Specjalne, Kardiologia po Dyplomie 2006; 4-11.Boh M, Opolski G, Polonski L, et al. Polownanie skutecznosci i bezpieczenstwa stosowania atorwastatyny generycznej i referencyjnej u osob zwiekszonego ryzyka wiencowego z hiperlipidemia. Wydanie Specjalne, Kardiologia po Dyplomie 2006; 4-11.

The authors declare that there are no conflicts of interest present.